NINSIPAPOGENE SIBARNAREPVEC
UNII Y70X1GJT61

Substance Identification & Data

This profile provides standardized clinical and technical data for Ninsipapogene Sibarnarepvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Y70X1GJT61.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2640294-04-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
Y70X1GJT61
CAS Registry Number
2640294-04-6
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
NINSIPAPOGENE SIBARNAREPVEC
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C204147
National Cancer Institute reference terminology for clinical and research data.
INN ID
12223
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
LM-174
Identifier assigned by the United States Adopted Names Council.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ninsipapogene Sibarnarepvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NINSIPAPOGENE SIBARNAREPVEC

Common Names & Synonyms

NINSIPAPOGENE SIBARNAREPVEC [USAN]
RECOMBINANT REPLICATION-COMPETENT ATTENUATED ARENAVIRUS (PICHINDE VIRUS (PICV)) VECTOR WITH TWO COPIES OF THE SMALL (S) GENOME SEGMENT (S RNA SEGMENT) WITH ONE ENCODING THE VIRAL MEMBRANE GLYCOPROTEIN (GP) AND ONE ENCODING THE VIRAL NUCLEOCAPSID PROTEIN (NP), AND BOTH ENCODING A SYNTHETIC HUMAN PAPILLOMAVIRUS TYPE 16 E7E6 FUSION PROTEIN (WITH MUTATIONS OF C24G, E26G AND C91G IN E7, AND C69G AND C112G IN E6), AND WITH A WILD TYPE LARGE (L) GENOME SEGMENT (L RNA SEGMENT). EXPRESSION OF THE E7E6 FUSION PROTEIN IS UNDER CONTROL OF THE VIRAL EXPRESSION MECHANISM
RNA (ATTENUATED REPLICATING PICHINDE VIRUS VECTOR HB-202 SEGMENT L), SUPRAMOLECULAR COMPLEX WITH RNA (ATTENUATED REPLICATING PICHINDE VIRUS VECTOR HB-202 SEGMENT S2 HUMAN PAPILLOMAVIRUS 16 (24-GLYCINE,26-GLYCINE,91-GLYCINE) GENE E7 PROTEIN FUSION PROTEIN WITH (69-GLYCINE,112-GLYCINE) GENE E6 PROTEIN TRANSGENE PLUS MEMBRANE GLYCOPROTEIN GPC-SPECIFYING), SUPRAMOLECULAR COMPLEX WITH RNA (ATTENUATED REPLICATING PICHINDE VIRUS VECTOR HB-202 SEGMENT S1 HUMAN PAPILLOMAVIRUS 16 (24-GLYCINE,26-GLYCINE,91-GLYCINE) GENE E7 PROTEIN FUSION PROTEIN WITH (69-GLYCINE,112-GLYCINE) GENE E6 PROTEIN TRANSGENE PLUS NUCLEOCAPSID PROTEIN-SPECIFYING)

Technical Codes

HB-202 COMPONENT R3PICV-E7E6

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus